Skip to content

Study · Animal study (in vivo) · mouse · 2025

4 results

MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model.

Wu N, Shen C, Wang J, Chen X, Zhong P

Cardiovascular drugs and therapy23 Dec 2023Cited by 11 (Europe PMC)

PMID38141139 (opens in a new tab)DOI10.1007/s10557-023-07540-2 (opens in a new tab)PepBankPUB-38141139
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with streptozotocin-induced type 1 diabetes, MOTS‑c treatment ameliorated diabetes-associated myocardial function abnormalities.

    In plain wordsIn mice with type 1 diabetes, MOTS‑c improved heart function problems compared with no MOTS‑c.

    Peptide
    MOTS-c
    Outcome
    IncreaseMyocardial function abnormalities
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetic cardiomyopathy
    Comparator
    No MOTS-c
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous osmotic pump · 12 weeksAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c treatment markedly ameliorated these diabetes-associated myocardial function and structure abnormalities.
    3 context sentences
    Summary · context
    The results showed that diabetic mice exhibited significant cardiac dysfunction, dilatation, and adverse cardiac remodeling.
    Summary · context
    Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection.
    Summary · context
    After diabetes establishment, the mice were randomly dividend into two groups treated with or without MOTS-c peptide, which was administered subcutaneously by osmotic pump for 12 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with streptozotocin-induced type 1 diabetes, MOTS‑c treatment ameliorated diabetes-associated myocardial structure abnormalities.

    In plain wordsIn mice with type 1 diabetes, MOTS‑c reduced heart structure problems compared with no MOTS‑c.

    Peptide
    MOTS-c
    Outcome
    DecreaseMyocardial structure abnormalities
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetic cardiomyopathy
    Comparator
    No MOTS-c
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous osmotic pump · 12 weeksAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c treatment markedly ameliorated these diabetes-associated myocardial function and structure abnormalities.
    3 context sentences
    Summary · context
    The results showed that diabetic mice exhibited significant cardiac dysfunction, dilatation, and adverse cardiac remodeling.
    Summary · context
    Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection.
    Summary · context
    After diabetes establishment, the mice were randomly dividend into two groups treated with or without MOTS-c peptide, which was administered subcutaneously by osmotic pump for 12 weeks.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with streptozotocin-induced type 1 diabetes, MOTS‑c reversed the deactivation of AMPK signaling in the heart.

    In plain wordsIn mice with type 1 diabetes, MOTS‑c restored the AMPK signal in the heart.

    Peptide
    MOTS-c
    Outcome
    IncreaseAMPK signaling in the diabetic heart
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetic cardiomyopathy
    Comparator
    No MOTS-c
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous osmotic pump · 12 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, MOTS-c reversed AMPK signaling deactivation
    2 context sentences
    Summary · context
    Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection.
    Summary · context
    After diabetes establishment, the mice were randomly dividend into two groups treated with or without MOTS-c peptide, which was administered subcutaneously by osmotic pump for 12 weeks.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with streptozotocin-induced type 1 diabetes, MOTS‑c inhibited inflammation in the diabetic heart.

    In plain wordsIn mice with type 1 diabetes, MOTS‑c reduced heart inflammation compared with no MOTS‑c.

    Peptide
    MOTS-c
    Outcome
    DecreaseInflammation in the diabetic heart
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetic cardiomyopathy
    Comparator
    No MOTS-c
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous osmotic pump · 12 weeksAs given in this study (mouse).

    Source sentences

    Summary
    inhibited inflammation in the diabetic heart.
    2 context sentences
    Summary · context
    Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection.
    Summary · context
    After diabetes establishment, the mice were randomly dividend into two groups treated with or without MOTS-c peptide, which was administered subcutaneously by osmotic pump for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.